{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-169795","form_type":"8-K","ticker":"OSRH","cik":"0001840425","company_name":"OSR Holdings, Inc.","filed_at":"2024-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.658403+00:00","generated_at":"2026-06-01T01:08:37.176648+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Bellevue Life Sciences Acquisition Appoints Sang Hyun Kim as Director","bullets":["Appointed Sang Hyun Kim as director effective June 23, 2024; fills Audit, Compensation, and M&A Committee vacancies.","Mr. Kim is Special Advisor of Marketing, Private Equity Funds at Korea Daesung Asset Management Co., Ltd.","Has ~11 years at Samsung Group including Global M&A Strategy at Samsung Asset Management.","Board determined Mr. Kim meets Nasdaq independence standards; no compensation for director role.","Mr. Kim entered into standard Letter Agreement and Indemnity Agreement with BLAC."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-169795","json":"https://secwatch.observer/filing/0001193125-24-169795.json","markdown":"https://secwatch.observer/filing/0001193125-24-169795.md","text":"https://secwatch.observer/filing/0001193125-24-169795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840425/000119312524169795/0001193125-24-169795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840425/000119312524169795/d835518d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:08:37.176648+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3aabaccc36","claim":"Sang Hyun Kim was appointed as Director at OSR Holdings, Inc..","evidence_excerpt":"On June 23, 2024, the Board of Directors (the “Board”) of Bellevue Life Sciences Acquisition Corp. (the “Company”) appointed Mr. Sang Hyun Kim as a director, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000119312524169795/0001193125-24-169795-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}